|Bid||88.44 x 21500|
|Ask||88.47 x 900|
|Day's Range||88.44 - 88.48|
|52 Week Range||42.00 - 89.15|
|Beta (5Y Monthly)||0.27|
|PE Ratio (TTM)||37.47|
|Earnings Date||Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.50|
NEW YORK, NY / ACCESSWIRE / November 20, 2020 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * BioSpecifics Technologies Corp.
NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:BioSpecifics Technologies Corp.
Endo International plc (Nasdaq: ENDP) ("Endo") today announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with the previously announced tender offer by Beta Acquisition Corp., a wholly-owned indirect subsidiary of Endo ("Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share (the "Offer Price"), net to the holder in cash, without interest and less any applicable withholding taxes (the "Offer"). The Offer, which commenced on November 2, 2020, is being made pursuant to the previously announced Agreement and Plan of Merger, dated October 19, 2020, by and among Endo, Merger Sub and BioSpecifics (as it may be amended from time to time, the "Merger Agreement").